Zepbound targets a second hormone called glucose-dependent insulinotropic polypeptide (GIP) to promote weight loss
We dont do that with other chronic diseases. The trial-and-error system It takes time to develop a treatment plan with GLP-1 drugs that works with each individual patient, said Dr
This suggests retatrutide continues working beyond one year without the plateau seen with some other weight loss interventions
What is true is that patients who are of lower income, suffer the complications of the disease more often
The question that arises is no longer, "Does it work? But, "Who owns the next generation mechanism? Were likely entering a phase where: Large-cap pharma consolidates metabolic platforms Mid-cap biotech becomes an acquisition target (mechanism-driven) Valuations increasingly reflect mechanism optionality, not single indications And importantly: The winners may not be the first GLP-1 players But those building next-gen metabolic architectures Bottom line: If GLP-1 were the opening trade, multi-pathway metabolic drugs may represent the full cycle
doi:10.3390/cells9030740 178